Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms

Higher neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been associated with increased risk of thrombosis, cardiovascular mortality, but their role in myeloproliferative neoplasms (MPN) remains unclear. We analyzed NLR and PLR as prognostic markers for thrombosis and...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2024-11, Vol.103 (11), p.4545-4556
Main Authors: Cvetković, Mirjana, Arsenović, Isidora, Smiljanić, Mihailo, Sobas, Marta, Bogdanović, Andrija, Leković, Danijela
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - blood
Blood Platelets - pathology
Female
Fusion Proteins, bcr-abl - blood
Hematology
Humans
Lymphocyte Count
Lymphocytes
Male
Medicine
Medicine & Public Health
Middle Aged
Myeloproliferative Disorders - blood
Myeloproliferative Disorders - complications
Myeloproliferative Disorders - diagnosis
Myeloproliferative Disorders - mortality
Neutrophils
Oncology
Platelet Count
Prognosis
Retrospective Studies
Thrombosis
Thrombosis - blood
Thrombosis - etiology
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Higher neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been associated with increased risk of thrombosis, cardiovascular mortality, but their role in myeloproliferative neoplasms (MPN) remains unclear. We analyzed NLR and PLR as prognostic markers for thrombosis and overall survival (OS) in the study that included 461 consecutive MPN patients who were diagnosed from 2018 to 2022 at University center. Twenty age-matched patients without hematological disorder were used as controls. NLR and PLR were significantly increased in whole MPN group compared to controls. NLR was highest in PV > PMF > ET ( p   PMF > PV ( p  
ISSN:0939-5555
1432-0584
1432-0584
DOI:10.1007/s00277-024-06023-0